Cizutamig for systemic sclerosis
Part of Skin clinical trials.
This early-stage study tests an experimental drug called cizutamig for people with systemic sclerosis (a disease that causes hardening of the skin and can affect internal organs). It aims to see if the drug is safe and may help reduce skin thickening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have a confirmed diagnosis of systemic sclerosis (scleroderma).
- Have the type of scleroderma that affects the skin widely, including areas above the elbows and knees.
- Have had the disease for 7 years or less.
- Have tried standard treatments without enough improvement.
- Not have severe stomach or gut complications, or active kidney or nerve problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
This trial tests an experimental tablet called TollB-001 to see if it can help people with a type of systemic sclerosis that affects the skin and internal organs. It may reduce symptoms and slow the disease.
This study tests a new biologic drug called cizutamig for people with active lupus (SLE) who haven't gotten enough help from standard treatments. The goal is to see if it can safely reduce disease activity.
This trial tests an experimental drug called cizutamig for people with rheumatoid arthritis that hasn't responded to other treatments. It aims to see if a new approach can help control the disease in patients who still have active inflammation despite trying other advanced therapies.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.